Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / United Kingdom / GT Biopharma

United Kingdom & GT Biopharma

2 shared events · Importance 3 · Last updated May 27, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the NewsDesk Dashboard
Shared Events (2)
55
Business
Hansa Biopharma Idefirix PAES Results
United Kingdom: The United Kingdom participated in the PAES study, contributing to the data that supports the efficacy and safety of Imlifidase.
GT Biopharma: GT Biopharma announced positive topline results from its European Post Authorization Efficacy Study for Imlifidase, fulfilling a key requirement for full marketing authorization and boosting its product's market potential.
May 27, 2026 · 6 articles
52
Business
SERB_Pharmaceuticals acquires Idefirix rights
United Kingdom: The United Kingdom>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
GT Biopharma: GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.
May 19, 2026 · 7 articles
NEWSDESK
Explore this relationship live

Track how United Kingdom and GT Biopharma interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.